Acquired by Eurofins Pharma Discovery Services in 2017, Eurofins DiscoverX is dedicated to the development and commercialization of innovative solutions for discovery research.
Proven Technology
The Company pioneered the use of β-galactosidase enzyme fragment complementation (EFC) for discovery research. EFC technology is a proven, established screening platform in most major pharmaceutical companies and our EFC-based HitHunter® cAMP assays are the market leader in GPCR screening applications. PathHunter® and InCELL Hunter™ technology platforms, an adaptation of EFC technology, are an innovative and comprehensive assay system that enables live cell-based assays for pathway profiling and compound screening.
In addition to the EFC platform, Eurofins DiscoverX also holds extensive intellectual property for its second core technology, an in vitro binding assay platform called KINOMEscanSM. Through our core technologies, Eurofins DiscoverX is able to offer assay solutions for every major class of drug target, including GPCRs, kinases, bromodomains, methyltranseferases, proteases, nuclear hormone receptors, cytokines, transcription factors and secreted proteins.
Corporate Partnerships
Eurofins DiscoverX remains committed to fully exploit the commercial potential of its EFC as well as KINOMEscan technology either solely or with its corporate partners. Eurofins DiscoverX values such partnerships and is actively seeking additional collaborative alliances to commercialize and provide early access to new technology platforms in the drug discovery and development markets.